AR047533A1 - Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa - Google Patents

Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa

Info

Publication number
AR047533A1
AR047533A1 ARP050100427A ARP050100427A AR047533A1 AR 047533 A1 AR047533 A1 AR 047533A1 AR P050100427 A ARP050100427 A AR P050100427A AR P050100427 A ARP050100427 A AR P050100427A AR 047533 A1 AR047533 A1 AR 047533A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
alkenyl
heteroaryl
heterocycle
Prior art date
Application number
ARP050100427A
Other languages
English (en)
Inventor
Bang-Chi Chen
Roberto Droghini
Jean Lajeunesse
Marco John D Di
Michael Galella
Chidambaram
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34864498&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR047533A1 publication Critical patent/AR047533A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicacion 1: U proceso para preparar un compuesto que tiene la formula (1), en donde L, Ar, R2, R3, R4, R5, y m son como se definen abajo, caracterizado porque comprende hacer reaccionar un compuesto que tiene la formula (2), en donde Q es el grupo -O-P*, en donde P* se selecciona de manera que, cuando se considera junto con el átomo de O al cual P* se enlaza, Q es un grupo saliente, y Ar, L, R2, R3, y m son como se definen a continuacion, con un reactiva halogenante seguido por un compuesto de tiourea que tiene la formula (3), en donde, R4 y R5 son como se definen a continuacion, para proporcionar el compuesto de formula (1), en donde, Ar es el mismo en las formulas (1) y (2) y es arilo o heteroarilo; L es el mismo en las formulas (19 y (2) y es alquileno opcionalmente sustituido; R2 es el mismo en las formulas (1) y (2), y se selecciona de H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, heteroarilo, cicloalquilo, y heterociclo; R3 es el mismo en las formulas (1) y (2), y se selecciona de H, halogeno, ciano, haloalquilo, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, arilo, heteroarilo, cicloalquilo, y heterociclo; R4 es (i) el mismo en cada una de las formulas (1) y (3), y (ii) es independientemente seleccionado de H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, heteroarilo, cicloalquilo, y heterociclo, o alternativamente, R4 se toma junto con R5 para formar heteroarilo o heterociclo; R5 es (i) el mismo en cada una de las formulas (1) y (3), y (ii) es independientemente seleccionado de H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, arilo, heteroarilo, cicloalquilo, y heterociclo, o alternativamente, R5 se toma junto con R4 para formar heteroarilo o heterociclo; y m es 0 o 1.
ARP050100427A 2004-02-06 2005-02-04 Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa AR047533A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54249004P 2004-02-06 2004-02-06
US62493704P 2004-11-04 2004-11-04

Publications (1)

Publication Number Publication Date
AR047533A1 true AR047533A1 (es) 2006-01-25

Family

ID=34864498

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100427A AR047533A1 (es) 2004-02-06 2005-02-04 Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa

Country Status (27)

Country Link
EP (1) EP1711481B2 (es)
JP (2) JP5148115B2 (es)
KR (2) KR101310427B1 (es)
AR (1) AR047533A1 (es)
AT (1) ATE453630T1 (es)
AU (1) AU2005212405B2 (es)
BR (1) BRPI0507476B8 (es)
CA (1) CA2555291C (es)
CY (1) CY1109907T1 (es)
DE (1) DE602005018601D1 (es)
DK (1) DK1711481T4 (es)
ES (1) ES2337272T5 (es)
GE (1) GEP20094804B (es)
HK (1) HK1091835A1 (es)
HR (1) HRP20100166T4 (es)
IL (1) IL177280A (es)
IN (1) IN2014DN06567A (es)
NO (1) NO338049B1 (es)
NZ (1) NZ548613A (es)
PE (1) PE20050691A1 (es)
PL (1) PL1711481T5 (es)
PT (1) PT1711481E (es)
RU (1) RU2382039C2 (es)
SI (1) SI1711481T2 (es)
TW (1) TWI338004B (es)
WO (1) WO2005077945A2 (es)
ZA (1) ZA200606242B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200600513A (en) 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
WO2006121742A2 (en) * 2005-05-05 2006-11-16 Bristol-Myers Squibb Company Formulations of a src/abl inhibitor
WO2007019210A1 (en) * 2005-08-05 2007-02-15 Bristol-Myers Squibb Company Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives
US20070105867A1 (en) * 2005-09-21 2007-05-10 Bristol-Myers Squibb Company Oral administration of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070219370A1 (en) * 2006-03-15 2007-09-20 Bristol-Myers Squibb Company Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino] -5-thiazolecarboxamide and related metabolites thereof
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
PL2508523T5 (pl) 2007-10-23 2020-08-10 Teva Pharmaceutical Industries Ltd. Odmiany polimorficzne dasatynibu i sposób ich wytwarzania
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) * 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
JP5620979B2 (ja) * 2009-05-05 2014-11-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐ３８キナーゼ阻害剤
CN101812060B (zh) * 2010-02-02 2011-08-17 南京卡文迪许生物工程技术有限公司 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物
EP2359813A1 (en) 2010-02-04 2011-08-24 Ratiopharm GmbH Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid
JP5589097B2 (ja) * 2010-02-08 2014-09-10 南京▲か▼文迪許生物工程技術有限公司 ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
CN102250084A (zh) * 2010-02-08 2011-11-23 南京卡文迪许生物工程技术有限公司 达沙替尼多晶型物及其制备方法和药用组合物
WO2013065063A1 (en) 2011-11-03 2013-05-10 Cadila Healthcare Limited Anhydrous form of dasatinib, process for its preparation and its use
KR20150020683A (ko) 2012-06-15 2015-02-26 바스프 에스이 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정
CN102827156A (zh) * 2012-09-11 2012-12-19 湖南欧亚生物有限公司 一种达沙替尼的新的工业合成方法
CN103819469A (zh) * 2012-11-16 2014-05-28 重庆医药工业研究院有限责任公司 一种达沙替尼的晶型及其制备方法
CZ306598B6 (cs) 2012-12-06 2017-03-22 Zentiva, K.S. Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu
CN103880833B (zh) * 2012-12-19 2018-04-06 北京本草天源药物研究院 达沙替尼一水合物的新晶形及其制备方法和药物组合物
WO2014102759A2 (en) 2012-12-31 2014-07-03 Ranbaxy Laboratories Limited Process for the preparation of dasatinib and its intermediates
CN103319476B (zh) * 2013-06-13 2015-12-02 济南德爱医药技术有限公司 一种激酶抑制剂
KR101831535B1 (ko) 2013-07-25 2018-02-22 바스프 에스이 무정형 형태의 다사티닙 염
KR20160023879A (ko) * 2013-07-25 2016-03-03 바스프 에스이 결정질 형태의 다사티닙 염
CN104341410A (zh) * 2013-08-09 2015-02-11 上海科胜药物研发有限公司 一种达沙替尼新晶型及其制备方法
CN103483289B (zh) * 2013-09-06 2016-01-27 浙江科源化工有限公司 一种2-氨基-n-(2-氯-6-甲基苯基)噻唑-5-甲酰胺的合成方法
WO2015107545A1 (en) 2013-12-18 2015-07-23 Dharmesh Mahendrabhai Shah Water soluble salts of dasatinib hydrate
CZ306732B6 (cs) * 2013-12-19 2017-05-31 Zentiva, K.S. Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu
AU2015200822A1 (en) 2014-03-11 2015-10-01 Cerbios-Pharma Sa Process and intermediates for the preparation of dasatinib
RU2567537C1 (ru) * 2014-04-23 2015-11-10 Олег Ростиславович Михайлов Кристаллическая безводная дельта-модификация n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамида, способ ее получения и фармацевтическая композиция на ее основе
HU231013B1 (hu) * 2014-05-26 2019-11-28 Egis Gyógyszergyár Zrt. Dasatinib sók
US10301302B2 (en) 2015-06-29 2019-05-28 Msn Laboratories Private Limited Crystalline forms of N-(2-chloro-6-methy]phenvn-2-[F6-[4-(2-hvdroxvethvl)-L-piperazin-vil-2-methvil-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof
WO2017098391A1 (en) * 2015-12-11 2017-06-15 Shilpa Medicare Limited Process for the preparation of dasatinib
CN105474831B (zh) * 2015-12-16 2017-11-17 湖南省西瓜甜瓜研究所 一种白芨裸种消毒方法
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
CN105503854A (zh) * 2015-12-31 2016-04-20 哈药集团技术中心 一种达沙替尼无水合物的新晶型物及其制备方法
BR112018015891A2 (pt) 2016-02-03 2018-12-26 Dr Reddys Laboratories Ltd formas de estado sólido de dasatinib e processos para sua preparação
WO2017144109A1 (en) 2016-02-25 2017-08-31 Remedica Ltd Dasatinib formulation
CN105830582B (zh) * 2016-04-15 2018-05-01 成都大学 一种白及种子的快速回土培育方法
GB201608587D0 (en) 2016-05-16 2016-06-29 Univ Dundee Treatment of opiod tolerance
CN106117195A (zh) * 2016-06-09 2016-11-16 青岛辰达生物科技有限公司 一种用于治疗白血病的药物达沙替尼的合成方法
IT201700006157A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristalli di un composto antitumorale
IT201700006145A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristallo di un composto antitumorale
JP6597727B2 (ja) 2017-05-11 2019-10-30 東洋インキＳｃホールディングス株式会社 表面保護用粘着剤および粘着シート
AU2018297710A1 (en) * 2017-07-07 2020-02-27 Biocon Limited Polymorphic forms of dasatinib
HRP20221196T1 (hr) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019241504A1 (en) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Kinase inhibitor salts and compositions thereof
CN109369638B (zh) * 2018-11-21 2020-07-07 山东罗欣药业集团股份有限公司 一种达沙替尼的制备工艺
CN109503568B (zh) * 2018-12-29 2020-08-07 山东罗欣药业集团股份有限公司 一种达沙替尼的制备方法
CN112409349A (zh) * 2019-08-20 2021-02-26 湖南华纳大药厂股份有限公司 激酶抑制剂及其制备、药物组合物和用途
IL294928A (en) 2020-01-24 2022-09-01 Nanocopoeia Llc Amorphous solid dispersions of dasatinib and uses thereof
GB2592680A (en) 2020-03-06 2021-09-08 Zentiva Ks Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
EP4071248A1 (en) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Means and methods for enhancing receptor-targeted gene transfer
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN114634421A (zh) * 2022-02-24 2022-06-17 济宁晟泰药业有限公司 一种达沙替尼中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3505055A (en) * 1966-12-07 1970-04-07 Uniroyal Inc Method of controlling plant growth with carboxamidothiazoles
US5514643A (en) * 1993-08-16 1996-05-07 Lucky Ltd. 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms
IL144910A0 (en) * 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
DE602004028907D1 (de) * 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
ATE481134T1 (de) * 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
KR20060124692A (ko) 2006-12-05
KR20120097424A (ko) 2012-09-03
HK1091835A1 (en) 2007-01-26
DK1711481T3 (da) 2010-04-19
NO338049B1 (no) 2016-07-25
IL177280A (en) 2013-09-30
HRP20100166T1 (hr) 2010-05-31
ES2337272T5 (es) 2013-09-30
NO20063780L (no) 2006-10-27
NZ548613A (en) 2010-05-28
KR101310427B1 (ko) 2013-09-24
BRPI0507476A (pt) 2007-07-17
EP1711481B1 (en) 2009-12-30
RU2006131591A (ru) 2008-03-20
PL1711481T5 (pl) 2013-10-31
PT1711481E (pt) 2010-02-25
JP5148115B2 (ja) 2013-02-20
EP1711481A2 (en) 2006-10-18
WO2005077945A3 (en) 2006-05-18
SI1711481T2 (sl) 2013-10-30
BRPI0507476B1 (pt) 2020-12-08
SI1711481T1 (sl) 2010-03-31
BRPI0507476B8 (pt) 2021-05-25
PL1711481T3 (pl) 2010-05-31
HRP20100166T4 (en) 2013-09-30
IN2014DN06567A (es) 2015-07-10
WO2005077945A2 (en) 2005-08-25
ZA200606242B (en) 2008-01-08
CA2555291C (en) 2017-01-17
DK1711481T4 (da) 2013-08-26
ES2337272T3 (es) 2010-04-22
TW200530205A (en) 2005-09-16
DE602005018601D1 (de) 2010-02-11
RU2382039C2 (ru) 2010-02-20
PE20050691A1 (es) 2005-09-25
GEP20094804B (en) 2009-10-26
EP1711481B2 (en) 2013-05-22
AU2005212405A1 (en) 2005-08-25
JP2012188446A (ja) 2012-10-04
CY1109907T1 (el) 2014-09-10
IL177280A0 (en) 2006-12-10
JP2007521340A (ja) 2007-08-02
TWI338004B (en) 2011-03-01
CA2555291A1 (en) 2005-08-25
AU2005212405B2 (en) 2010-08-12
ATE453630T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
AR047533A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la quinasa
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
AR082864A2 (es) Preparacion de compuestos de aminopirimidina
ECSP034611A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina
DOP2011000061A (es) Compuestos de pirrol
CU23926B1 (es) Derivado de oxopirazina y herbicida
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
CO6150142A2 (es) Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
DK1838677T3 (da) Krystallinske former af (R)-8-chlor-1.methyl-2,3,4,5-tetrahydro-1H-3-benzazepinhydrochlorid
GT200500286A (es) Analogos de anilino-pirimidina
EA200601457A1 (ru) Ингибиторы вирусной полимеразы
CO6801736A2 (es) Derivados heterocíclicos de amina
WO2007046513A3 (en) Benzoylurea compounds and use thereof
AR052058A1 (es) Metodo para producir un compuesto de sal (4.5-dihidroisoxasol-3-yl) tiocarboxamidina
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
AR065352A1 (es) Derivados de piridil-triazolopirimidina, pesticidas que los contienen y proceso para prepararlos.
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR055666A1 (es) Inhibidores inntr
ATE402185T1 (de) Verfahren für fluorcytidinderivate
AR055420A1 (es) Derivados de pirimidina sustituidos
AR060962A1 (es) Proceso de preparacion de derivados de quinazolina e intermediarios de sintesis
EA200700767A1 (ru) Способ получения пиразолов
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
ATE443053T1 (de) Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate

Legal Events

Date Code Title Description
FC Refusal